Bridgebio Pharma vs Legend Biotech
Legend Biotech is the larger business, with $1.03bn of revenue in fiscal 2025 against $502m for Bridgebio Pharma (2.0 times as much). Bridgebio Pharma grew faster (126.3% against 64.0%). Legend Biotech kept more of each dollar of sales as profit: a net margin of -28.8% against -144.4%.
| Latest fiscal year | Bridgebio PharmaBBIO, 2025 | Legend BiotechLEGN, 2025 |
|---|---|---|
| Revenue | $502m | $1.03bn |
| Revenue growth | 126.3% | 64.0% |
| Net income | −$725m | −$297m |
| Operating margin | -104.2% | -13.3% |
| Net margin | -144.4% | -28.8% |
| Return on equity | — | -29.1% |
| Free cash flow | −$447m | −$129m |
| Cash | $570m | $902m |
| Total debt | $2.01bn | $319m |
| Debt to equity | — | 31.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $48.3m | — |
| Employees | 834 | — |
| Market value | $14.64bn | $3.97bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 143 sales | 0 buys, 5 sales |